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Abstract: 
Lysergic N,N-diethylamide (LSD) is perhaps one of the most intriguing 
psychoactive substances known and numerous analogs have been explored 
to a varying extent in previous decades. In 2013, N6-allyl-6-norlysergic 
acid diethylamide (AL-LAD) and (2’S,4’S)-lysergic acid 2,4-
dimethylazetidide (LSZ) have appeared on the ‘research chemicals’ / new 
psychoactive substances (NPS) market in both powdered and blotter form. 
This study reports the analytical characterization of powdered AL-LAD and 
LSZ tartrate samples and their semi-quantitative determination on blotter 
paper. Included in this study was the use of nuclear magnetic resonance 
spectroscopy, gas chromatography mass spectrometry (MS), low and high-
resolution electrospray MS(/MS), high performance liquid chromatography 
diode array detection and GC solid-state infrared analysis. One feature 
shared by serotonergic psychedelics, such as LSD, is the ability to mediate 
behavioral responses via activation of 5-HT2A receptors. Both AL-LAD and 
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LSZ displayed LSD-like responses in male C57BL/6J mice when employing 
the head-twitch response (HTR) assay. AL-LAD and LSZ produced nearly 
identical inverted-U-shaped dose-dependent effects, with the maximal 
responses occurring at 200 µg/kg. Analysis of the dose-responses by 
nonlinear regression confirmed that LSZ (ED50 = 114.2 nmol/kg) was 
equipotent to LSD (ED50 = 132.8 nmol/kg) in mice, whereas AL-LAD was 
slightly less potent (ED50 = 174.9 nmol/kg). The extent to which a 
comparison in potency can be translated directly to humans requires 
further investigation. Availability of both chemical and pharmacological 
data obtained from NPS as they appear on the market provides important 
data to research communities that are interested in various aspects related 
substance use and forensic identification. 
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Abstract 
 
Lysergic N,N-diethylamide (LSD) is perhaps one of the most intriguing psychoactive 
substances known and numerous analogs have been explored to a varying extent in 
previous decades. In 2013, N6-allyl-6-norlysergic acid diethylamide (AL-LAD) and 
(2’S,4’S)-lysergic acid 2,4-dimethylazetidide (LSZ) have appeared on the ‘research 
chemicals’ / new psychoactive substances (NPS) market in both powdered and 
blotter form. This study reports the analytical characterization of powdered AL-LAD 
and LSZ tartrate samples and their semi-quantitative determination on blotter paper. 
Included in this study was the use of nuclear magnetic resonance spectroscopy, gas 
chromatography mass spectrometry (MS), low and high-resolution electrospray 
MS(/MS), high performance liquid chromatography diode array detection and GC 
solid-state infrared analysis. One feature shared by serotonergic psychedelics, such 
as LSD, is the ability to mediate behavioral responses via activation of 5-HT2A 
receptors. Both AL-LAD and LSZ displayed LSD-like responses in male C57BL/6J 
mice when employing the head-twitch response (HTR) assay. AL-LAD and LSZ 
produced nearly identical inverted-U-shaped dose-dependent effects, with the 
maximal responses occurring at 200 µg/kg. Analysis of the dose-responses by 
nonlinear regression confirmed that LSZ (ED50 = 114.2 nmol/kg) was equipotent to 
LSD (ED50 = 132.8 nmol/kg) in mice, whereas AL-LAD was slightly less potent (ED50 
= 174.9 nmol/kg). The extent to which a comparison in potency can be translated 
directly to humans requires further investigation. Availability of both chemical and 
pharmacological data obtained from NPS as they appear on the market provides 
important data to research communities that are interested in various aspects related 
substance use and forensic identification. 
 
Introduction 
 
Lysergic N,N-diethylamide (LSD, lysergide) (Figure 1) is perhaps one of the most 
intriguing psychoactive substances known, given how strongly it has impacted 
scientific and cultural events. The psychoactive properties of LSD were discovered 
serendipitously by Dr. Albert Hofmann in 1943.[1-5] Subsequently, numerous structural 
modifications of the prototypical lysergamide scaffold have been explored,[6] forming 
the basis for investigations into the nature of the receptor binding and functional 
activity of LSD.[7-11] In some cases, information about the effects of several 
lysergamides in humans is available.[12] 
 
Although not a new phenomenon,[13] the increasing rate at which ‘research chemicals’ 
or new psychoactive substances (NPS) have appeared on the market in recent years 
has attracted the attention of researchers and policy makers alike.[14-16] One LSD 
derivative, 1-propionyl-d-lysergic acid diethylamide (1P-LSD) (Figure 1), a substance 
that had never appeared in published literature, was recently encountered on the 
‘research chemical’ market. Investigations carried out in the authors’ laboratories 
characterized 1P-LSD using analytical and behavioral techniques.[17] 
 
Two other lysergamides, (8β)-N,N-diethyl-6-(prop-2-en-1-yl)-9,10-didehydroergoline-
8-carboxamide, also known as N6-allyl-6-norlysergic acid diethylamide and AL-LAD, 
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and [(2S,4S)-2,4-dimethylazetidin-1-yl][(8β)-6-methyl-9,10-didehydroergolin-8-
yl]methanone, i.e. (2′S,4′S)-lysergic acid 2,4-dimethylazetidide (LSZ, LA-SS-Az), 
appeared on the ‘research chemicals’ market in 2013, but have received little 
attention in the published literature. The first report of LSZ detection was received by 
the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in 
December 2013,[18] whereas detection of AL-LAD was reported for the first time in 
February 2015.[19]   
 
AL-LAD is one of several lysergamides that have been modified at the N6-
position.[7,12] The synthesis of AL-LAD was first described in 1976.[20] The substance 
was also synthesized by Hoffman and Nichols using a modified procedure published 
in 1985.[21] Like LSD, AL-LAD induces hyperthermia in rabbits.[22] When tested in the 
isolated rat uterus preparation, AL-LAD was found to have a more potent contractile 
effects than LSD.[23] The first investigation of the hallucinogen-like activity of AL-LAD 
was conducted by Hoffman and Nichols, who found that AL-LAD produced full 
substitution in rats trained to discriminate 0.08 mg/kg LSD tartrate.[21] Furthermore, 
the potency of AL-LAD in the drug discrimination paradigm (ED50 = 13 nmol/kg) 
exceeded that of LSD (ED50 = 46 nmol/kg).
[21] Receptor binding studies revealed that 
AL-LAD had high affinity for 5-HT2A receptors labeled with [
3H]ketanserin (Ki = 8.1 
nM) and ([125I]-R-DOI (Ki = 3.4 nM) in rat frontal cortex homogenates.
[8,24] 
Subsequently, it was shown that AL-LAD displayed slightly lower affinity than LSD for 
D1 (K0.5 = 189 nM vs. [
3H]SCH-23390) and D2 (K0.5 12.3 nM vs. [
3H]spiperone in the 
presence of ketanserin) dopaminergic receptors.[25]   
 
The isomers of lysergic acid 2,4-dimethylazetidide (LSZ) were prepared to gain 
further insight into the binding orientation of LSD and to help map the topography of 
the 5-HT2A receptor. Specifically, the 2,4-dimethylazetidide analog of LSD was 
pursued as a sterically constrained version of the N,N-diethylamide group.[26] 
Because the presence of a 2,4-dimethylazetidide moiety gives rise to two additional 
chiral centers, Nichols et al. synthesized three isomers of LSZ: cis-(meso)-, trans-
(2’R,4’R)-, and trans-(2’S,4’S)-LSZ. Drug discrimination studies confirmed that all 
three isomers produce full substitution in LSD-trained rats and showed that the 
(2’S,4’S) isomer (ED50 = 25 nmol/kg) was more potent than LSD, whereas the other 
two isomers were less potent (ED50 cis = 115 nmol/kg; ED50 (2’R,4’R) = 134 nmol/kg) 
and only the (2’S,4’S) isomer fully substituted in rats trained to discriminate the 5-
HT1A agonist LY-293284. Receptor binding studies showed that of the three LSZ 
isomers, the (2’S,4’S) isomer had activity most similar to LSD at a range of 
monoamine receptors.[26,27] An emerging body of evidence suggests that 5-HT2A-
mediated agonist effects also may play an important role in the manifestation of anti-
inflammatory responses.[5] The first indications for this came from investigations with 
the classical serotonergic psychedelic (R)-2,5-dimethoxy-4-iodoamphetamine (DOI), 
which was found to suppress tumor necrosis factor (TNF)-α-induced inflammation 
processes in a number of tissues, for example by inhibition of pro-inflammatory gene 
expression.[28] Interestingly, (2’S,4’S)-LSZ was also able to induce a TNF-α-mediated 
increase in pro-inflammatory gene expression at concentrations of 1 and 50 nM,[28,29] 
consistent with its ability to function as a 5-HT2A receptor agonist. These particular 
properties may have been the reason why (2’S,4’S)-LSZ was included in more 
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recently published patent literature associated with hyposmia (smell loss) and the 
treatment of viral infections.[30,31] 
 
Although available on the ‘research chemical’ market for some time, a 
comprehensive analytical characterization has not yet been described in detail for 
either AL-LAD or LSZ. Some data, however, have been published for AL-LAD, 
including the analysis of both the 8α and 8β epimers (iso-AL-LAD and AL-LAD, 
respectively) by nuclear magnetic resonance spectroscopy (NMR), the 
implementation of high performance liquid chromatography (HPLC) triple quadrupole 
tandem mass spectrometry (MS/MS) used for the generation of tandem mass 
spectra,[32] and a chemiluminescent nitrogen detection method coupled to HPLC.[33]  
 
The present investigation aimed to fill this knowledge gap by performing an extensive 
characterization of powdered AL-LAD and LSZ samples and commercially obtained 
blotter paper samples (photographs supplied as Supporting Information). Included in 
this approach was the use of NMR, gas chromatography mass spectrometry (GC-
MS), high-resolution electrospray MS/MS, HPLC diode array detection, HPLC 
quadrupole MS, and GC solid-state infrared analysis. A semi-quantitative analysis of 
AL-LAD and LSZ blotters was also incorporated. 5-HT2A receptor activation plays a 
central role in the mediation of psychedelic effects in humans.[3,5] Likewise, 5-HT2A 
activation is responsible for the head-twitch response (HTR), a behaviour often used 
to assess hallucinogen-like effects in rodents.[34,35] Because it was predicted that both 
AL-LAD and LSZ would induce the HTR, a test of this behavioral response was 
included in this investigation using a quantitative, magnetometer-based approach.[35] 
 
Experimental 
 
Materials 
 
All chemicals used were of analytical or HPLC grade and were obtained either from 
Aldrich (Dorset, UK), Rathburn Chemicals Ltd (Walkerburn, Scotland, UK) or Fisher 
Scientific (Dublin, Ireland). Powdered samples of (2’S,4’S)-lysergic acid 2,4-
dimethylazetidide (LSZ) and N6-allyl-6-norlysergic acid diethylamide (AL-LAD) 
tartrate were obtained from Synex Ltd. (London, UK). Blotters labeled to contain 150 
µg AL-LAD and 150 µg LSZ, and blank blotter paper, were provided by the same 
vendor. LSD was used as an internal standard (stock solution at 1 mg/mL) and 
purchased from Cerilliant (Round Rock, TX, USA). A synthesized reference sample 
of (2’S,4’S)-LSZ hemitartrate was available from work published previously.[26]  
 
Instrumentation  
 
Nuclear magnetic resonance spectroscopy  
 
NMR spectra were recorded in d6-DMSO (Sigma-Aldrich, St. Louis, MO, USA) using 
an Agilent DD2-700 spectrometer with an Agilent HFCN cryogenically cooled 5-mm 
probe (1H at 699.81 MHz; 13C at 175.98 MHz) (Agilent, Santa Clara, CA, USA). 
Proton spectra were acquired using 64 scans with a 45° pulse (3.6 µs) and a 5.0 
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s relaxation delay, collecting 50223 points, with an acquisition time of 4.5 s and 
spectral window of 11160 Hz. Carbon spectra were acquired using 4096 scans with a 
30° pulse (3.6 µs), WALTZ-16 decoupling, and a 0.2 s relaxation delay, collecting 
64k data points, with an acquisition time of 1.57 s and spectral window of 41667 Hz. 
Suggested assignments were aided by 1-D and 2-D experiments. Internal chemical 
shift references were based on residual solvent peaks. 
 
Gas chromatography mass spectrometry  
 
Electron ionization (EI) mass spectra (70 eV) were recorded using a Finnigan TSQ 
7000 triple stage quadrupole mass spectrometer coupled to a gas chromatograph 
(Trace GC Ultra, Thermo Electron, Dreieich, Germany). Sample introduction was 
carried out using a CTC CombiPAL (CTC Analytics, Zwingen, Switzerland) 
autosampler. The emission current was 200 µA and the scan time was 1 s spanning 
a scan range between m/z 29 – m/z 600. The ion source temperature was 
maintained at 175 °C. Samples were introduced via gas chromatography with 
splitless injection using a fused silica capillary DB-1 column (30 m × 0.25 mm, film 
thickness 0.25 µm). The temperature program consisted of an initial temperature of 
80 °C, held for 1 min, followed by a ramp to 280 °C at 15 °C/min. The final 
temperature was held for 21 min. The injector temperature was 220 °C. The transfer 
line temperature was maintained at 280 °C and the carrier gas was helium in 
constant flow mode at a flow rate of 1.0 mL/min. Approximately 2 mg were dissolved 
in 1.5 mL methanol. For analysis, 1 µL sample solution was injected into the GC-MS 
system. Retention indices (RI) are given as Kovats Indices calculated from 
measurement of a n-alkane mixture analyzed with the above mentioned temperature 
program. 
 
High-resolution electrospray mass spectrometry  
Ultrahigh-performance liquid chromatography quadrupole time-of-flight single and 
tandem mass spectrometry (UHPLC-QTOF-MS/MS) data were recorded on an 
Agilent 6540 UHD Accurate-Mass Q-TOF LC-MS system coupled to an Agilent 1290 
Infinity UHPLC system (Agilent, Cheshire, UK). Chromatographic separation was 
achieved using an Agilent Zorbax Eclipse Plus C18 column (100 mm × 2.1 mm, 1.8 
µm) (Agilent, Cheshire, UK). Mobile phases used for UHPLC separation consisted of 
100% acetonitrile (1% formic acid) and an aqueous solution of 1% formic acid. The 
column temperature was set at 40 °C (0.6 mL/min) and data were acquired for 5.5 
min. The elution was a 5–70% acetonitrile gradient ramp over 3.5 min, then 
increased to 95% acetonitrile in 1 min and held for 0.5 min before returning to 5% 
acetonitrile in 0.5 min. QTOF-MS data were acquired in positive mode scanning from 
m/z 100 – m/z 1000 with and without auto MS/MS fragmentation. Ionization was 
achieved with an Agilent JetStream electrospray source and infused internal 
reference masses. Agilent 6540 QTOF-MS parameters: gas temperature 325 °C, 
drying gas 10 L/min and sheath gas temperature 400 °C. Internal reference ions at 
m/z 121.05087 and m/z 922.00979 were used for calibration purposes.   
 
Liquid chromatography diode array detection 
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HPLC-DAD was carried out on a Dionex 3000 Ultimate liquid chromatography 
system coupled to a UV diode array detector (Thermo Fisher, St. Albans, UK), using 
a Phenomenex Synergi Fusion column (150 mm × 2mm, 4 µm) protected by a 4 mm 
× 3 mm Phenomenex Synergi Fusion guard column (Phenomenex, Cheshire, UK). 
Mobile phases used were 70% acetonitrile with 25 mM of triethylammonium 
phosphate buffer (TEAP) and aqueous solution of 25 mM TEAP buffer. A gradient 
elution started from 4% acetonitrile and ramped to 70% acetonitrile in 15 min and 
held for 3 min, with total acquisition time of 18 min at a flow rate of 0.6 mL/min. The 
diode array detection window was set at 200 nm – 595 nm (collection rate 2 Hz).  
 
Liquid chromatography electrospray mass spectrometry 
 
LC-MS analyses were performed on an Agilent 1100 system. Separation was 
obtained on a Restek (Bellefonte, PA, USA) Allure PFPP column (5 µm, 50 x 2.1 
mm). Mobile phase A consisted of 0.1% formic acid in water, whereas, mobile phase 
B consisted of 0.1% formic acid in acetonitrile. The Agilent LC-MSD settings were as 
follows: positive electrospray mode, capillary voltage 3500 V, drying gas (N2) 12 
L/min at 350 °C, nebulizer gas (N2) pressure 50 psi, Scan mode m/z 70 – 500, 
fragmentor voltage 150 V. The sample for LC-MS analysis was dissolved in 
acetonitrile/water (1:1, containing 0.1% formic acid) at a concentration of 10 µg/mL. 
The injection volume was 1 µL, flow rate was 0.80 mL/min and the column 
temperature was 30 °C. The total run time was 25 min. The following gradient elution 
program was used: 0–2 min 2% B, followed by an increase to 60% within 15 min, 
then up to 80% within 20 min, returning to 2% within 25 min. 
 
Gas chromatography solid-state infrared analysis 
 
The methanolic solution was measured on a GC-solid phase-IR-system consisting of 
an Agilent GC 7890B (Waldbronn, Germany) with probe sampler Agilent G4567A 
and a DiscovIR-GC™ (Spectra Analysis, Marlborough, MA, USA). The column eluent 
was cryogenically accumulated on a spirally rotating ZnSe disk that was cooled by 
liquid nitrogen. The IR spectra were directly recorded through the IR-transparent 
ZnSe disk using a nitrogen-cooled MCT detector. GC parameters: the injection was 
carried out in splitless mode with an injection port temperature of 240 °C and a DB-1 
fused silica capillary column (30 m × 0.32 mm i.d., 0.25 µm film thickness). The 
carrier gas was helium with a flow rate of 2.5 mL/min; oven temperature program: 
80 °C for 2 min, ramped to 290 °C at 20 °C/min, and held at the final temperature for 
25 min. The transfer line heater was set at 280 °C. Infrared conditions: oven 
temperature, restrictor temperature, disc temperature, and Dewar cap temperatures 
were 280 °C, 280 °C, −40 °C, and 35 °C, respectively. The vacuum was 0.2 mTorr, 
disc speed 3 mm/s, spiral separation was 1 mm, wavelength resolution 4 cm-1 and IR 
range 650–4000 cm-1. Acquisition time was 6s/file with 64 scans/spectrum. Data 
were processed using GRAMS/AI Ver. 9.1 (Grams Spectroscopy Software Suite, 
Thermo Fischer Scientific) followed by implementation of the OMNIC Software, Ver. 
7.4.127 (Thermo Electron Corporation, Dreieich, Germany). 
 
Liquid chromatography ultraviolet detection used for analysis of blotters 
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HPLC analyses were performed on a Hitachi LaChrom Elite system that comprised 
an L-2130 pump, L-2200 autosampler, L-2300 column oven, and L-2400 UV detector, 
respectively (Hitachi High Technologies America, Inc., San Jose, CA, USA). The 
detection wavelength was set at 250 nm. Separation was obtained using a Zorbax 
Eclipse Plus C18 column (5 µm, 250 mm × 4.6 mm) from Agilent Technologies 
(Santa Clara, CA, USA). Mobile phase A consisted of methanol with 0.1% formic acid 
(v/v) and mobile phase B was aqueous 10 mM ammonium formate titrated to pH 3.3. 
The following gradient was used for elution: 0–2 min 28% B, followed by an increase 
to 43% within 22 min and held for 6 min. This was followed by a decrease to 28% B 
within 3 min and held for 7 min to give a total run time of 40 min. Chromatograms 
were analyzed using the Agilent OpenLAB CDS EZChrom Edition (Agilent 
Technologies, Santa Clara, CA, USA).  
 
Analyses of blotter samples 
 
A sample buffer containing LSD as internal standard (LSD buffer) was prepared by 
diluting a 1 mg/mL stock solution to a final concentration of 0.025 mg/mL using a 
50:50 mixture of mobile phase A and B. Powdered LSZ and AL-LAD were dissolved 
in LSD buffer to give a stock concentration of 1 mg/mL, and then diluted to desired 
concentration levels at 250, 200, 150, 100, 50, and 10 µg/mL, respectively. The 
injection volume of samples was 10 µL, flow rate was 0.6 mL/min, and the column 
temperature was set at 35 °C using an external column oven from Cole-Parmer 
(Illinois, USA) to account for the column length of 25 cm.  
 
Blank blotter paper was spiked with 100 µL of a solution of 100 µg LSZ or AL-LAD 
per mL of methanol and dried at room temperature protected from light. One hundred 
µL of a 100 µg/mL solution were added separately to an amber vial and dried in a 
desiccator to serve as a control sample. Dried blotters were transferred to amber 
vials and extracted three times with LSD buffer (333, 333, and 334 µL) using an 
ultrasonic bath (Branson 1800, Danbury, CT, USA) at room temperature. The 
combined extracts were analyzed without further dilution by HPLC and compared to 
the control samples to determine recovery from the spiked blotter paper. LSZ and 
AL-LAD blotters were analyzed in the same manner as described for the control 
blotters.  
 
Head-twitch response assays 
 
Male C57BL/6J mice (6−8 weeks old) were obtained from Jackson Laboratories (Bar 
Harbor, ME, USA) and housed up to four per cage with a reversed light-cycle (lights 
on at 1900 h, off at 0700 h). Food and water were provided ad libitum, except during 
behavioral testing, which was performed between 1000 h and 1830 h. The head 
twitch response (HTR) was detected using a head mounted magnet and a 
magnetometer coil, as described previously.[35] Behaviour was monitored for 30 min 
immediately after IP injection of vehicle (saline) or drug. The injection volume was 5 
mL/kg. HTR counts were analyzed by one-way ANOVA and post-hoc comparisons 
were made using Tukey’s studentized range method. Significance was demonstrated 
by surpassing an α-level of 0.05.  ED50 values and 95% confidence limits were 
calculated using nonlinear regression. 
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Results and discussion 
 
Analytical characterization 
 
Electron ionization (EI) mass spectra for AL-LAD and LSZ are shown in Figures 2 
and 3B–D. The molecular ions for both compounds displayed a high relative 
abundance (m/z 349 for AL-LAD and m/z 335 for LSZ) that have also been observed 
for other lysergamides such as 1P-LSD and LSD.[17] Suggested fragmentation 
pathways have been added as Supporting Information and follow on from those 
previously described and discussed in detail for 1P-LSD and LSD.[17] The structural 
similarity between AL-LAD and LSD (Figure 1) revealed the presence of similar 
fragment ions (Supporting Information). Examples include the iminium ion at m/z 72 
or the retro Diels-Alder species at m/z 280 (Figure 2, Supporting Information). The 
loss of an allyl radical from the nitrogen at the 6-position was represented by the 
formation of a prominent fragment at m/z 308. In the spectrum of LSZ, the presence 
of the azetidine group shifted the retro Diels-Alder fragment to m/z 292 (Figure 3D). 
Other similarities observed in the mass spectra between LSD and AL-LAD included 
fragment clusters between m/z 151 – m/z 154 and m/z 178 – m/z 182 and these 
have also been observed in the EI mass spectra of 1P-LSD, LSD, and LSZ (Figure 
3B–3D, Supporting Information).[17] AL-LAD product ions have been reported 
previously following triple quadrupole MS/MS analysis. Some of the product ions 
detected in the present study were in agreement although the m/z 309 detected here 
was not reported previously.[32] 
 
An interesting observation was made during GC-MS analysis of LSZ. As shown in 
Figure 3A, three major, distinct peaks were detected and the corresponding EI mass 
spectra are shown in Figure 3B–3D. At first glance, the similarity of these mass 
spectra suggested the detection of three LSZ isomers and a closer inspection 
revealed that some differences were also noticeable, especially in the mass range 
m/z 223 – m/z 337. Interestingly, only the mass spectrum of LSZ-III (Figure 3D) 
showed the retro Diels-Alder fragment at m/z 292. It seemed conceivable that these 
additional isomers might have been formed as a consequence of GC-induced 
conditions (e.g. heat and/or active sites) that might have led to this isomerization 
phenomenon. Furthermore, the mass spectra of two additional peaks of 
comparatively minor abundance (Figure 3A) at 26.29 and 26.72 min have also been 
included as Supporting Information. It has to be noted that the minor differences in 
retention times mentioned here and those shown on Figure 3A reflected a minor 
difference in peak picking. In total, five isomeric mass spectra have been detected 
but it was not possible to identify the exact configuration. As shown below, HPLC 
single quadrupole MS analysis of the powdered LSZ material revealed the presence 
of a diastereomer when implementing analysis of the protonated molecule at m/z 350 
in single ion monitoring mode. Whether this minor peak reflected the presence of the 
8α-epimer (iso-LSZ) could not be confirmed although it appeared to be a likely 
candidate.  
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Ultra high-performance liquid chromatography electrospray ionization accurate mass 
quadrupole time-of-flight tandem mass spectrometry (UHPLC-ESI-QTOF-MS/MS) 
data for AL-LAD are displayed in Figure 4, with suggested dissociation pathways as 
Supporting Information. The two most abundant product ions observed under QTOF-
MS/MS conditions were m/z 309.18410 and m/z 208.09945, respectively. In the case 
of the former, the loss of the allyl group from the protonated molecule (C22H28N3O
+) 
would have been consistent with C19H23N3O
•+ (309.18356, ∆ = 1.75 ppm), whereas 
the latter might have been consistent with C14H12N2
•+ (208.09950, ∆ = −0.24 ppm). As 
suggested in the Supporting Information, the m/z 208 product ion might have formed 
due to the loss of an allyl radical from an intermediate species at m/z 249.13837 
(C17H17N2
+, 249.13862, ∆ = −1.00 ppm). Figure 4B and 4C display the mass spectra 
obtained from analysis by HPLC-ESI single quadrupole mass spectrometry (LC-Q-
MS) at two different fragmentor voltages. At these settings, sufficient in-source 
collision-induced dissociation (CID) allowed for the detection of product ions, most 
notably at m/z 309, 281 and 208 (Figure 4B). The sodiated adduct ions were also 
present at m/z 372. The analysis of powdered AL-LAD material by LC-Q-MS in 
selected ion monitoring mode (SIM) revealed only one visible peak (Figure 4D), 
suggesting the absence of a diastereomer, which was somewhat surprising because 
the powdered material showed significant discoloration (Supporting Information). The 
UV spectrum recorded by HPLC diode array detection (DAD) is presented in Figure 
4E and is consistent with the sp ctrum recorded for LSD (Supporting Information).  
 
UHPLC-ESI-QTOF-MS/MS, LC-Q-MS and LC-DAD data collected from LSZ are 
summarized in Figure 5, with suggested dissociation pathways in the Supporting 
Information section. As was the case with AL-LAD, the LSZ-derived counterpart of 
the m/z 281 ion in the AL-LAD spectrum was observed at m/z 293.16470 
(C19H21N2O
+, 293.16484, ∆ = −0.48 ppm). Similarly, loss of 2,4-dimethylazetidine-1-
carbaldehyde might have given rise to m/z 223.12345 (C15H15N2
+, 223.12297, ∆ = 
2.15 ppm). The m/z 223 ion might have also been formed via the formation of an 
oxonium intermediate (C16H15N2O
+, 251.11789, ∆ = −0.40 ppm), followed by a neutral 
loss of CO (Supporting Information). The corresponding oxonium intermediate in the 
AL-LAD spectrum would have been expected at m/z 277.13354 (C18H17N2O
+) before 
yielding the m/z 249 ion, but the m/z 277 species was not observed in any 
appreciable abundance. The LC-Q-MS investigation in SIM mode revealed the 
presence of a second peak at 11.52 min (Figure 5F), labeled as LSZ-2, which 
indicated the potential presence of a diastereomer, for example iso-LSZ, although 
that could not be confirmed due to the lack of authentic reference material. The LC-
DAD spectrum recorded for LSZ was comparable to the spectrum of AL-LAD (Figure 
4E) and LSD (Supporting Information).  
 
Following analysis of both lysergamides by GC-MS, the solid-state infrared (IR) 
spectra of the eluents were recorded when cryogenically deposited on a spirally 
rotating cryogenically cooled zinc selenide disk. The advantage of this approach was 
that the solidified free base material was measured, which circumvented a problem 
encountered with several other lysergamides where mixtures of salt forms can occur 
due to changes during storage and polymorphism.[36] The ATR-FTIR spectrum of AL-
LAD is shown in Figure 6. Key features also observed for LSD, such as the C=O and 
C-N stretch or C-H out-of-plane deformations suggested to be associated with the 
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indole ring, have also been observed.[36-39] The NH bands at higher wavenumbers 
were present as expected but this was not observed previously in the spectrum 
recorded for 1P-LSD under identical conditions due to the attachment of the 
propionyl group.[17] As described above, GC-MS analysis of LSZ revealed the 
detection of what appeared to be LSZ isomers. The three most predominant peaks 
LSZ-I – LSZ-III (Figure 3A) not only displayed some differences in the mass spectra, 
but inspection of the corresponding IR spectra also uncovered some minor 
differences. Figure 7 shows partial, overlaid spectra of LSZ isomers I – III to facilitate 
the comparison. All complete spectra can be found as Supporting Information.  
 
The LSZ, both in powdered and blotter form and obtained as a ‘research chemical’, 
was manufactured and sold as the trans-(2’S,4’S)-isomer, which was consistent with 
results acquired by using a chiral HPLC method (Supporting Information). The 
comparison with the synthesized (2’S,4’S)-isomer[26] revealed the same retention 
time, which suggested that the ‘research chemical’ products were consistent with the 
information provided on the product label. However, without the comparison with the 
(2’R,4’R)-form, the possibility of co-elution could not be fully excluded. The amounts 
of AL-LAD and LSZ extracted from blotters were estimated based on the use of the 
available powdered material as the standard for calibration purposes at different 
concentration levels. However, LSZ was available as a synthesized standard. When 
employing this HPLC method, r tention times observed for LSD (I.S.), LSZ, and AL-
LAD were 28.39, 29.33, and 32.15 min, respectively (Supporting Information). Table 
1 provides a summary of extracted amounts of AL-LAD and LSZ from blotters that 
were both labeled to contain 150 µg. Estimations of recovery were based on the 
extraction of identical blank blotter papers that had been used for the manufactured 
blotters. Recovery values obtained from spiked blank blotters were 91.5% (AL-LAD) 
and 93.3% (LSZ), respectively. The amounts of AL-LAD and LSZ on the 
commercially prepared blotters were estimated based on the recovery rates (Table 1). 
As mentioned below, the proton NMR data recorded for LSZ revealed that the 
integrals for tartaric acid (~1.6H instead of either 1H or 2H) had to be taken into 
account, thus, leading to LSZ results to be expressed as freebase equivalents. AL-
LAD results, on the other hand, were expressed based on the hemitartrate salt in 
alignment with NMR measurements. Since certified reference material was not 
available, the results obtained were considered semi-quantitative. The purity of AL-
LAD powder was not known (see HPLC trace in Supporting Information) and since 
this material was used for constructing the calibration curve, the results obtained 
from this determination were also considered tentative.  
 
Chemical shifts recorded by nuclear magnetic resonance spectroscopy (NMR) were 
assigned using chemical shift position, multiplicities, as well as 2-D spectra including 
HQSC and COSY. α and β 1H chemical shifts were assigned using the approach 
described previously.[17] The chemical shift positions and multiplicities of the 1H NMR 
spectra recorded for AL-LAD were compared with previous reports published by 
Hoffman and Nichols[21] and Stachulski et al.[40] Slight differences in chemical shift 
position was likely due to the use of CDCl3 in the earlier study compared to d6-DMSO 
used here. The current assignments, provided in Table 2, expand upon earlier 
reports in which a number of the chemical shifts were not assigned. 13C NMR 
assignments for AL-LAD did not appear to have been available in the reported 
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literature. The C-22 carbon gave separate 13C chemical shifts at 41.50 and 39.48 
ppm, which was due to non-equivalence of these methylene carbons and hindered 
rotation about the amide C-N bond. The 13C NMR shift at 39.48 ppm was found to 
couple to a single quartet (2H) at 3.31 ppm, suggesting free rotation of this CH2 and 
coupling with the CH3 of H-23. In the case of the 41.50 ppm shift, the HSQC showed 
coupling to two doublet of quartets at 3.46 and 3.40 ppm. This splitting pattern is 
consistent with the fact that this is a prochiral site and the distinct chemical 
environment experienced by these protons relative to one another and the other C-
22 protons. Thus, these doublets of quartets resulted from germinal coupling (J = 
14.4 Hz) and vicinal coupling (J = 7.2 Hz) with the CH3 of H-23. This phenomenon 
was also observed with 1P-LSD.[17] Another point worth noting was the integration of 
the tartaric acid peak in the 1H spectra at 4.26 ppm. This shift integrated to 1 proton 
consistent with the hydrogen 2,3-dihydroxybutanoate (hemitartrate) salt of AL-LAD.  
 
The 1H spectrum of LSZ was consistent with that published previously (hemitartrate 
in d6-DMSO) by Nichols et al.
[26] The NMR data ruled out the presence of the cis-form 
but differentiation between the two trans enantiomers was not possible. 1H chemical 
shift assignments of LSZ and 13C NMR data for LSZ have not been previously 
reported. Assignments were made in the same manner as AL-LAD and are provided 
in Table 3. In contrast to AL-LAD, the tartaric acid proton shift at 4.22 ppm integrated 
to ~1.6 protons. This integration was inconsistent with the hemi- or stoichiometric 
tartrate salts, giving a ratio of LSZ:tartaric acid of 1:0.8. This could be due to a mixed 
salt (hemi and stoichiometric) or an excess of free tartaric acid present as an impurity 
in the hemitartrate salt.[39] The 1H and 13C chemical shifts of the dimethylazetidine 
ring were as expected. In the 1H spectrum, the H-21 protons gave two separate 
multiplets at 4.66 – 4.59 ppm and 4.39 – 4.31 ppm. The two methyl groups (H-22) 
were assigned to two doublets at 1.44 and 1.35 ppm due to coupling (J = ~6.2 Hz) 
with H-21. In contrast, cis-LSZ H-22 protons appeared (no assignments given) to 
give a single multiplet at 1.28 – 1.41 ppm integrating to 6H.[26] The H-23 protons of 
the dimethylazetidine ring were assigned to two separate doublets of doublets of 
doublets at 1.99 and 1.95 ppm from both geminal and vicinal couplings.  
 
Head-twitch response 
 
The head twitch response (HTR) was assessed for 30 min following administration of 
AL-LAD and LSZ. Both lysergamides induced the HTR (AL-LAD: F5,26 = 20.45, 
p<0.0001; LSZ: F5,25 = 15.52, p<0.0001; Figure 8).  As shown in Table 4, AL-LAD and 
LSZ produced nearly identical inverted-U-shaped dose-dependent effects, with the 
maximal responses occurring at 200 µg/kg. The effects of LSD on HTR, published in 
an earlier study, are included in Table 4 for comparison. Analysis of the dose-
responses by nonlinear regression confirmed that LSZ was equipotent to LSD in 
mice, whereas AL-LAD was slightly less potent (Table 4). The potency values 
(nmol/kg) determined for LSZ were corrected based on the proton NMR data (0.8 
molar equivalent of tartaric acid relative to LSZ). The magnitude of the maximal 
response to AL-LAD, as far as the HTR counts were concerned (mean ± SEM = 53.0 
± 2.4), was greater than that of LSZ (33.6 ± 2.7). Normalizing the responses 
Page 12 of 29
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 12
(as %baseline) confirmed that AL-LAD induced a significantly larger response than 
LSZ (t9 = 7.02, p<0.0001).  
 
1P-LSD has also been shown to induce the HTR.[17] In contrast to AL-LAD and LSZ, 
however, 1P-LSD was found to be significantly less potent than LSD.  There is some 
evidence that the maximum number of head twitches induced by a compound in rats 
may reflect its efficacy at the 5-HT2A receptor.
[41] To the extent that such a 
relationship exists in mice, the present results indicate that AL-LAD and especially 
LSZ may activate 5-HT2A receptors with lower relatively efficacy compared with LSD.  
Alternatively, lysergamides exhibit activity at other receptors, including 5-HT1A and 5-
HT2C, which may attenuate expression of the HTR.  
 
Conclusion 
 
Both AL-LAD and LSZ were confirmed to induce LSD-like behavioural effects in mice, 
which added a multidisciplinary layer to the analytical characterization work 
described in the present study. The provision of a diverse set of chemical and 
pharmacological data obtained from new psychoactive substances as they appear on 
the market provides important data to research communities that are focused on 
various aspects of substance use and forensic identification. Further studies seem 
warranted to clarify the psychopharmacological properties of these substances.  
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Figure 1. Structural representations of AL-LAD, LSZ and related lysergamides.  
54x14mm (300 x 300 DPI)  
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Figure 2. Electron ionization mass spectrum recorded for AL-LAD.  
138x109mm (300 x 300 DPI)  
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Figure 3. (A). Partial gas chromatography mass spectrometry trace where five LSZ isomers were detected. 
Three major isomers were labeled as LSZ I–III. Two minor isomers were also detected at 26.30 and 26.76 
min. The corresponding mass spectra are shown as Supporting Information. (B). Electron ionization mass 
spectrum (EI-MS) recorded for LSZ isomer I.  
277x401mm (300 x 300 DPI)  
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Figure 3. (C) and (D). Electron ionization mass spectra recorded for LSZ isomers II and III.  
292x430mm (300 x 300 DPI)  
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Figure 4. Comparison of electrospray ionization single and tandem mass spectra. (A). Quadrupole time of 
flight tandem mass spectrum (ESI-QTOF-MS/MS) recorded for AL-LAD. (B) and (C). In-source CID spectra of 
AL-LAD under single quadrupole mass spectrometry (HPLC-Q-MS) conditions. (D). HPLC-Q-MS trace using 
the m/z value of the protonated molecule for selected ion monitoring (SIM). (E). HPLC diode array analysis 
of AL-LAD.  
245x294mm (300 x 300 DPI)  
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Figure 5. Comparison of electrospray ionization single and tandem mass spectra. (A). Quadrupole time of 
flight tandem mass spectrum (ESI-QTOF-MS/MS) recorded for LSZ. (B)/(C) and (D)/(E): In-source CID 
spectra of LSZ-I and LSZ-II under single quadrupole mass spectrometry (HPLC-Q-MS) conditions. (F). HPLC-
Q-MS trace using the m/z value of the protonated molecule for selected ion monitoring (SIM). (G). HPLC 
diode array analysis of LSZ.  
288x401mm (300 x 300 DPI)  
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Figure 6. GC-solid state-IR spectrum of AL-LAD. Top: entire scan range. Bottom: partial scan range.  
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Figure 7. Partial, overlaid GC-solid state-IR spectra of LSZ isomers I–III for comparison. Individual spectra 
including the entire scan range are available as Supporting Information.    
191x127mm (300 x 300 DPI)  
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Figure 8. Effects of AL-LAD (A) and LSZ (B) on the head twitch response. Data are presented as group 
means ± SEM for the entire 30-min test session. *p < 0.01, significant differences from vehicle control 
group (Tukey’s test).  
219x440mm (300 x 300 DPI)  
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Table 1. Semi-quantitative estimation of lysergamides on blotter samples 
a
 
AL-LAD 
Control blotter 
Added Detected Recovery 
[%] 
AL-LAD 
blotter 
b
 
Amount (± SD) Adjusted 
c
 
1 99.84 µg 90.46 µg 90.6 1 143.03 ± 1.36 µg 156.32 µg 
2 99.84 µg 92.97 µg 93.1 2 144.24 ± 1.36 µg 157.64 µg 
3 99.84 µg 90.69 µg 90.8 3 168.31 ± 1.47 µg 183.95 µg 
Mean 99.84 µg 91.37 µg 91.5 4 198.00 ± 1.61 µg 216.39 µg 
       
LSZ 
Control blotter 
   LSZ 
blotter 
d
 
Amount (± SD) Adjusted
 e
 
1 114.30 µg 107.32 µg 93.9 1 113.58 ± 2.03 µg 121.74 µg 
2 114.30 µg 105.86 µg 92.6 2 121.22 ± 2.09 µg 129.92 µg 
Mean 114.30 µg 106.59 µg 93.3 3 121.89 ± 2.10 µg 130.64 µg 
    4 104.11 ± 1.94 µg 111.59 µg 
a
 LSD was used as internal standard whereas synthesized (2’S,4’S)-LSZ and powdered AL-LAD material were 
used as standards. AL-LAD: r
2
 = 0.9999; slope ± SD: 0.02384 ± 0.00011; intercept ± SD: 0.004005 ± 0.016780. 
LSZ:  r
2
 = 0.9997; slope ± SD: 0.02778 ± 0.00024; intercept ± SD: 0.06352 ± 0.02953.  
 
b 
Based on AL-LAD hemitartrate (see NMR data).  
 
c 
Based on 91.5% recovery from control blotters. 
 
d 
Based on freebase equivalents (see NMR data).  
 
e 
Based on 93.3% recovery from control blotters. 
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Table 2. 
1
H and 
13
C NMR data for AL-LAD hemitartrate in d6-DMSO at 700 / 176 
MHz 
 
No. 
13
C [δ / ppm] 
1
H [δ / ppm] 
1 – 10.70 (d, J = 2.0 Hz, 1H) 
2 119.31 7.02 (t, J = 2.0 Hz, 1H) 
3 108.82 – 
4 26.60 3.53 (dd, J = 14.5, 5.4 Hz, 4β-H, 1H)  
2.55 – 2.46 (d, J = 11.8 Hz, 4α-H, 1H) 
a
 
5 59.71 3.38 – 3.34 (m, 5β-H, 1H) 
6 – – 
7 51.72 3.08 (dd, J = 11.1, 4.5 Hz, 7α-H, 1H) 
2.62 (t, J = 10.7 Hz, 1H), 7β-H, 1H) 
8 39.05 3.77 – 3.71 (m, 8α-H, 1H) 
9 120.31 6.23 (s, 1H) 
10 135.56 – 
11 127.47 – 
12 111.03 7.01 (d, J = 7.02, 1H)
 
 
13 122.28 7.05 (t, J = 7.6 Hz, 1H) 
14 109.83 7.18 (d, J = 7.9 Hz, 1H) 
15 133.78 – 
16 125.84 – 
17 56.35 3.66 (dd, J = 14.5, 4.8 Hz, 1H) 
3.18 (dd, J = 14.5, 8.0 Hz, 1H) 
18 134.68 5.97 (dddd, J = 17.7, 10.2, 8.0, 5.0 Hz, 1H) 
19 118.04 5.30 (d, J = 17.1 Hz, 1H) 
5.20 (d, J = 10.2 Hz, 1H) 
20 170.68 – 
21 – – 
22 41.50 3.46 (dq, J = 14.4, 7.2 Hz, 1H) 
3.40 (dq, J = 14.4, 7.2 Hz, 1H) 
22 39.48 3.31 (q, J = 7.1 Hz, 2H) 
23 14.81 1.17 (t, J = 7.0 Hz, 3H) 
23 13.07 1.06 (t, J = 7.0 Hz, 3H) 
TA 
b
 72.03 4.26 (s, 1H) 
TA
 b
 173.20 – 
a 
Overlapping with solvent 
 
b 
TA: tartaric acid
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Table 3. 
1
H and 
13
C NMR data for LSZ tartrate in d6-DMSO at 700 / 176 
MHz 
 
No. 
13
C [δ / ppm] 
1
H [δ / ppm] 
1 – 10.73 (d, J = 1.6 Hz, 1H) 
2 119.40 7.04 (t, J = 1.9 Hz, 1H)
a
 
3 108.44 – 
4 26.39 3.51 (dd, J = 14.5, 5.6 Hz, 4β-H, 1H) 
2.56 – 2.51 (m, 4α-H, 1H) 
b
 
5 62.41 3.21 – 3.16 (m, 5β-H, 1H) 
6 – – 
7 54.81 3.08 (dd, J = 11.0, 5.0 Hz, 7α-H, 1H) 
2.67 (t, J = 10.8 Hz, 7β-H, 1H) 
8 39.03 3.48 – 3.44 (m, 8α-H, 1H) 
9 119.23 6.25 (s, 1H) 
10 135.22 – 
11 126.85 – 
12 111.12 7.05 (d, J = 7.2 Hz, 1H)
c
 
13 122.33 7.07 (t, J = 7.2 Hz, 1H)
d 
14 109.96 7.20 (dd, J = 7.2, 1.3 Hz, 1H) 
15 133.83 – 
16 125.72 – 
17 42.98 2.54 (s, 3H) 
e
 
18 170.71 – 
19 – – 
20 – – 
21 55.74 4.66 – 4.59 (m, 1H) 
21 53.52 4.39 – 4.31 (m, 1H) 
22 22.51 1.44 (d, J = 6.2 Hz, 1H) 
22 20.10 1.35 (d, J = 6.3 Hz, 1H) 
23 31.26 1.99 (ddd, J = 11.1, 8.2, 5.8 Hz, 1H) 
1.95 (ddd, J = 11.1, 8.1, 5.1 Hz, 1H) 
TA 
f
 71.98 4.22 (s, ~1.6H) 
TA
 f
 173.37 – 
a 
Overlapping with H-12 and H-13. 
 
b 
Overlapping with 17-CH3 
 
c 
Overlapping with H-2 and H-13. 
 
d 
Overlapping with H-2 and H-12. 
 
e 
Overlapping with 4α-H 
 
f 
TA: tartaric acid
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Table 4.  Results of the head twitch response (HTR) studies 
Agent N Dose (µg/kg) HTR Counts  
(± SEM)
a
 
ED50 (µg/kg)
b
 ED50 (nmol/kg)
b
 
LSD
c
 5 0 3.8 (0.6)   
 5 50 40.8 (5.1) *   
 5 100 75.4 (11.4) *   
 5 200 83.8 (5.9) *   
 5 400 58.6 (2.9) * 52.9 (38.9–72.0) 132.8 (97.6–180.7) 
AL-LAD 5 0 5.0 (1.4)   
 5 25 10.0 (1.5)   
 5 50 23.6 (5.6) *   
 6 100 29.5 (3.8) *   
 6 200 53.0 (2.4) *   
 5 400 46.2 (7.6) * 74.2 (55.3–99.7) 174.9 (130.2–234.8) 
LSZ
d
 5 0 5.8 (1.3)   
 5 25 9.2 (2.6)   
 5 50 21.2 (3.2) *   
 6 100 27.5 (2.6) *   
 5 200 33.6 (2.7) *   
 5 400 28.6 (3.9) * 52.0 (37.3–73.5) 114.2 (82.0–159.1) 
a 
HTR was assessed for 30 min.  *p<0.01 vs vehicle (Tukey’s test) 
b 
With 95% confidence limits.  
c 
Previously reported by Halberstadt and Geyer.
[35]
 
d 
The potency calculation (in nmol/kg) was adjusted based on the proton NMR with regards to the LSZ / 
tartaric acid integrals.  
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